## ERRATUM

DOI: 10.3892/or.2019.6997

### OBP-801, a novel histone deacetylase inhibitor, induces M-phase arrest and apoptosis in rhabdomyosarcoma cells

CHIHIRO TOMOYASU, KEN KIKUCHI, DAISUKE KANEDA, SHIGEKI YAGYU, MITSURU MIYACHI, KUNIHIKO TSUCHIYA, TOMOKO IEHARA, TOSHIYUKI SAKAI and HAJIME HOSOI

Oncol Rep 41: 643-649, 2019; DOI: 10.3892/or.2018.6813

Subsequent to the publication of the above article, the authors have realized that errors were introduced into Fig. 4 at the typesetting stage. Essentially, in Fig. 4B, the P-value should have read as "P=0.13" (not as 0.013), and in Fig 4D, the labels for $OBP^-$ and $OBP^+$ were set the wrong way around. The correct version of Fig. 4, as originally submitted, is shown opposite.

The Editor apologizes to the authors for introducing these errors into their figure, and to the readership for any inconvenience caused.




Figure 4. OBP-801 inhibits ARMS tumor growth and improves survival *in vivo*. (A) Six mice xenografted with luciferase-positive Rh30 cells were treated with vehicle or OBP-801 (10 mg/kg) for 6 weeks, starting on day 3 after tumor injection. We measured tumor-derived bioluminescence starting 3 days after beginning the treatment. Scale bar, 3.0 cm (B and C) Effect of OBP-801 on tumor growth and body weight in nude mice with subcutaneous xenografted RMS tumors (Rh30). Points indicate the mean tumor volumes or body weights (n=4); bars, SD. (D) Kaplan-Meier survival curve of xenografted mice treated with vehicle or OBP-801.